DSM Biologics, a business unit of DSM Pharmaceutical products, said it has reached an agreement for the acquisition of the assets and associated business of the Rhobust technology from Danish Upfront Chromatography for pharmaceutical and other applications.

As a result of the acquisition, DSM Biologics will gain all rights for the commercialization of the Rhobust technology in various fields, including the pharma industry. The Rhobust technology will lead to further innovation in the downstream processing for the manufacturing of recombinant proteins and antibodies. DSM Biologics will continue to support all existing clients for this technology.

The parties have agreed to not disclose financial details.